ICAD iCAD, Inc.
iCAD, Inc. is a medical technology company, which engages in the provision cancer detection and therapy solutions. It operates through the Cancer Detection and Cancer Therapy segments. The Cancer Detection segment include image analysis and workflow products. The Cancer Therapy segment consists radiation therapy products. The company was founded in 1984 and is headquartered in Nashua, NH.
Company profile
Ticker
ICAD
Exchange
Website
CEO
Michael S. Klein
Employees
Incorporated in
Location
Fiscal year end
Sector
Industry (SEC)
3M • Boston Scientific • Baxter International • Stryker • Becton Dickinson & Co • Teleflex • ResMed • Hill-Rom • Integra Lifesciences • AngioDynamics ...
Former names
Howtek Inc
SEC CIK
Corporate docs
IRS number
20377419
ICAD stock data
()
Investment data
Securities sold
Number of investors
Calendar
11 May 20
8 Jul 20
31 Dec 20
News
Company financial data Financial data
| Quarter (USD) | Mar 20 | Dec 19 | Sep 19 | Jun 19 | |
|---|---|---|---|---|---|
| Revenue | 6.55M | 9.38M | 7.86M | 7.33M | |
| Net income | -11.81M | -3.35M | -2.96M | -3.53M | |
| Diluted EPS | -0.59 | -0.17 | -0.15 | -0.2 | |
| Net profit margin | -180% | -35.69% | -37.62% | -48.16% | |
| Operating income | -3.89M | -1.95M | -1.96M | -1.46M | |
| Net change in cash | -1.06M | -2.11M | -2.14M | 8.25M | |
| Cash on hand | 14.26M | 15.31M | 17.43M | 19.57M | |
| Cost of revenue | 2.04M | 2.22M | 1.8M | 1.6M |
| Annual (USD) | Dec 19 | Dec 18 | Dec 17 | Dec 16 | |
|---|---|---|---|---|---|
| Revenue | 31.34M | 25.62M | 28.1M | 26.34M | |
| Net income | -13.55M | -9.02M | -14.26M | -10.1M | |
| Diluted EPS | -0.74 | -0.54 | -0.87 | -0.63 | |
| Net profit margin | -43.24% | -35.19% | -50.73% | -38.34% | |
| Operating income | -6.4M | -8.13M | -14.17M | -9.97M | |
| Net change in cash | 3.13M | 2.8M | 802K | -6.7M | |
| Cash on hand | 15.31M | 12.19M | 9.39M | 8.59M | |
| Cost of revenue | 7.11M | 6.19M | 9.93M | 7.82M |
Financial data from iCAD earnings reports
Recent insider trades
| Date | Owner | Security | Transaction | Code | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|
| 30 Jun 20 | Patel Rakesh | Director Stock Option Common Stock | Grant | Aquire A | No | 9.99 | 3,055 | 30.52K | 3,055 |
| 30 Jun 20 | Sassine Andy | Director Stock Option Common Stock | Grant | Aquire A | No | 9.99 | 3,542 | 35.38K | 3,542 |
| 30 Jun 20 | Wood Susan Alyson | Director Stock Option Common Stock | Grant | Aquire A | No | 9.99 | 3,434 | 34.31K | 3,434 |
| 30 Jun 20 | Nathaniel Dalton | Director Stock Option Common Stock | Grant | Aquire A | No | 9.99 | 3,271 | 32.68K | 3,271 |
| 31 May 20 | Stevens Stacey M | Common Stock | Payment of exercise | Dispose F | No | 11.74 | 11,193 | 131.41K | 171,788 |
Institutional ownership Q1 2020
33.0% owned by funds/institutions
13F holders |
Current |
|---|---|
| Total holders | 66 |
| Opened positions | 25 |
| Closed positions | 17 |
| Increased positions | 27 |
| Reduced positions | 8 |
13F shares |
Current |
|---|---|
| Total value | 55.21M |
| Total shares | 7.54M |
| Total puts | 74K |
| Total calls | 95.6K |
| Total put/call ratio | 0.8 |
Largest owners |
Shares | Value |
|---|---|---|
| Vanguard | 999.89K | $7.34M |
| Parkman Healthcare Partners | 725.59K | $5.33M |
| Renaissance Technologies | 659.57K | $4.84M |
| G2 Investment Partners Management | 614.16K | $4.51M |
| EAM Investors | 510.67K | $3.75M |
| BLK BlackRock | 408.53K | $3M |
| Fairpointe Capital | 349.63K | $2.57M |
| EAM Global Investors | 245.62K | $1.8M |
| Manatuck Hill Partners | 210.4K | $1.54M |
| Millennium Management | 205.97K | $1.51M |
Financial report summary
?Management Discussion
- iCAD, Inc. is a global medical technology company providing innovative cancer detection and therapy solutions. The Company reports in two segments: Detection and Therapy.
- In the Detection segment, the Company’s solutions include (i) advanced image analysis and workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing the most prevalent cancers earlier, and (ii) a comprehensive range of high-performance, Artificial Intelligence and Computer-Aided Detection (CAD) systems and workflow solutions for 2D and 3D mammography, Magnetic Resonance Imaging (MRI) and Computed Tomography (CT).
- In the Therapy segment, the Company offers an isotope-free cancer treatment platform technology the Xoft Electronic Brachytherapy System (“Xoft System”). The Xoft System can be used for the treatment of early- stage breast cancer, endometrial cancer, cervical cancer and skin cancer. We believe the Xoft System platform indications represent strategic opportunities in the United States and international markets to offer differentiated treatment alternatives. In addition, the Xoft System generates additional recurring revenue for the sale of consumables and related accessories which will continue to drive growth in this segment.
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. sophomore Avg
|
|
New words:
Accessing, Aid, Alliance, Appointment, Artificial, assumption, ASU, attributable, avoid, aware, benchmark, brain, Brook, burden, care, China, circumstance, clarifying, code, Committee, Compensatory, compliant, comply, comprised, constant, consummation, coverage, COVID, customary, cutting, deadline, deduced, delayed, Departure, director, disrupted, disruption, distribute, distribution, dividend, duration, ease, Edition, effort, employee, employment, enacted, enroll, equivalent, ESPP, established, exempt, experienced, exposure, extinguishment, Facilitation, factor, forgoing, glioblastoma, global, globally, greater, grow, health, imposed, improve, inclusion, innovative, Intelligence, Interbank, internet, IORT, issuedASU, JMP, Jonathan, Journal, Klein, leaving, lender, LIBOR, licensed, light, London, long, macro, mailed, makea, Michael, mitigate, monetary, NH, nominate, Nominating, noncompliance, notice, onset, order, ordering, Organization, pandemic, past, payroll, person, point, power, prepay, prepayment, President, previously, print, program, proxy, pursue, reclassified, referenced, refrained, Relief, relieved, remote, removing, repay, response, retire, retirement, Rule, scenario, Secretary, simplify, Simplifying, smaller, Spit, split, spread, Stacey, stockholder, Street, submission, Suite, SVB, thereon, tied, travel, unable, unaccrued, unprecedented, update, variety, virtually, volume, vote, voting, waiver, Wall, week, Western, world, worsening, worth, written, wrote
Removed:
accrue, accruing, agree, agreed, arm, award, began, Bloomberg, bolster, borrow, borrowed, cap, capitalized, clinical, collectively, combine, commercially, cumulative, deducted, develop, digital, earliest, earned, EBITDA, exceeding, expanded, expedient, file, foregoing, Fourth, franchise, free, gathering, goal, guarantee, guaranteed, guideline, historic, identification, immaterial, implemented, indemnification, initially, installed, investment, leasing, lessee, lesser, LLC, mix, noted, opening, owed, practical, radiological, reduce, register, relation, repurchase, resale, retained, retrospective, review, short, solved, structurally, subscription, support, thereunder, twelve, unexercisable, unrestricted, upcoming, upgradeable, viable, warehouse, writing
Financial reports
10-Q
2020 Q1
Quarterly report
11 May 20
10-K/A
2019 FY
Annual report (amended)
29 Apr 20
10-K
2019 FY
Annual report
11 Mar 20
10-Q
2019 Q3
Quarterly report
14 Nov 19
10-Q
2019 Q2
Quarterly report
13 Aug 19
10-Q
2019 Q1
Quarterly report
15 May 19
10-K/A
2018 FY
Annual report (amended)
30 Apr 19
10-K
2018 FY
Annual report
29 Mar 19
10-Q
2018 Q3
Quarterly report
14 Nov 18
10-Q
2018 Q2
Quarterly report
14 Aug 18
Current reports
8-K
Other Events
6 Jul 20
8-K
Submission of Matters to a Vote of Security Holders
2 Jul 20
8-K
Entry into a Material Definitive Agreement
24 Jun 20
8-K
Departure of Directors or Certain Officers
29 May 20
8-K
Recent Equity Offering Strengthens Balance Sheet and Increases Operating Flexibility with focus on Brain Cancer Initiatives
11 May 20
8-K
Entry into a Material Definitive Agreement
27 Apr 20
8-K
Departure of Directors or Certain Officers
23 Apr 20
8-K
Entry into a Material Definitive Agreement
31 Mar 20
8-K
Strong Q4 2019 revenue growth of 35% driven by a 39% increase in revenue from iCAD’s AI Cancer Detection segment
28 Feb 20
8-K
Unregistered Sales of Equity Securities
25 Feb 20
Registration and prospectus
424B5
Prospectus supplement for primary offering
24 Apr 20
424B5
Prospectus supplement for primary offering
31 Mar 20
S-3
Shelf registration
10 Jan 20
S-8
Registration of securities for employees
19 Dec 19
424B5
Prospectus supplement for primary offering
14 Jun 19
424B5
Prospectus supplement for primary offering
12 Jun 19
424B3
Prospectus supplement
20 Feb 19
S-8
Registration of securities for employees
31 Jan 19
S-3
Shelf registration
31 Jan 19
S-3
Shelf registration
21 Nov 18
Proxies
DEF 14A
Definitive proxy
27 May 20
PRE 14A
Preliminary proxy
15 May 20
DEF 14A
Definitive proxy
8 Nov 19
DEF 14A
Definitive proxy
20 Nov 18
DEF 14A
Definitive proxy
20 Oct 17
DEF 14A
Definitive proxy
4 Apr 16
DEF 14A
Definitive proxy
30 Apr 15
PRE 14A
Preliminary proxy
17 Apr 15
DEF 14A
Definitive proxy
2 Apr 14
DEFA14A
Additional proxy soliciting materials
20 May 13
Other
SD
Conflict minerals disclosure
27 May 20
EFFECT
Notice of effectiveness
3 Feb 20
CORRESP
Correspondence with SEC
30 Jan 20
UPLOAD
Letter from SEC
15 Jan 20
SD
Conflict minerals disclosure
24 May 19
EFFECT
Notice of effectiveness
15 Feb 19
EFFECT
Notice of effectiveness
5 Dec 18
SD
Conflict minerals disclosure
30 May 18
SD
Conflict minerals disclosure
30 May 17
SD
Conflict minerals disclosure
20 May 16
Ownership
4
ICAD / NATHANIEL DALTON ownership change
1 Jul 20
4
ICAD / Susan Alyson Wood ownership change
1 Jul 20
4
ICAD / ANDY SASSINE ownership change
1 Jul 20
4
ICAD / Rakesh Patel ownership change
1 Jul 20
4
ICAD / Stacey M Stevens ownership change
2 Jun 20
4
ICAD / Stacey M Stevens ownership change
11 May 20
4
ICAD / R. Scott Areglado ownership change
11 May 20
4
ICAD / Jonathan Go ownership change
11 May 20
4
ICAD / Michael S Klein ownership change
11 May 20
4
ICAD / Michael S Klein ownership change
21 Apr 20
Patents
APP
Utility
System and Method for Assessing Breast Cancer Risk Using Imagery
28 May 20
This invention provides a system and method for assessing risk of a breast cancer diagnosis based upon imagery of tissue and (optionally) other patient-related factors.
GRANT
Utility
Lung segmentation and bone suppression techniques for radiographic images
15 Oct 19
Lung segmentation and bone suppression techniques are helpful pre-processing steps prior to radiographic analyzes of the human thorax, as may occur during cancer screenings and other medical examinations.